Platelets and infection - an emerging role of platelets in viral infection.

Assinger A. · 2014

Read Platelets and infection - an emerging role of platelets in viral infection. by Assinger A. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4270245.txt.

Introduction

Alice Assinger reviews the role of platelets in viral infection in Frontiers in Immunology, published in 2014. Platelets are best known for stopping bleeding, but they also take part in immune defense, and many viral infections switch them on or drive their counts down.

The review covers how viruses can act on platelets directly, how immune complexes and anti-platelet antibodies form, and how low platelet counts mark a poor outlook in sepsis. Platelets can help clear some viruses yet help others persist, so their role cuts both ways. The survey gives clinicians a clear view of when platelet changes in infection are a warning sign.

Catalog record

CREATORAssinger A.
YEAR2014
COLLECTIONPAPERS
FORMATTXT
FILE SIZE69 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4270245

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Platelets and Infection – An Emerging Role of Platelets in Viral Infection By Alice Assinger Published in: Frontiers in Immunology DOI: 10.3389/fimmu.2014.00649 ABSTRACT Platelets are anucleate blood cells that play a crucial role in the maintenance of hemostasis. While platelet activation and elevated platelet counts (thrombocytosis) are associated with increased risk of thrombotic complications, low platelet counts (thrombocytopenia) and several platelet function disorders increase the risk of bleeding. Over the last years, more and more evidence has emerged that platelets and their activation state can also modulate innate and adaptive immune responses and low platelet counts have been identified as a surrogate marker for poor prognosis in septic patients. Viral infections often coincide with platelet activation. Host inflammatory responses result in the release of platelet activating mediators and a pro-oxidative and pro-coagulant environment, which favors platelet activation. However, viruses can also directly interact with platelets and megakaryocytes and modulate their function. Furthermore, platelets can be activated by viral antigen–antibody complexes and in response to some viruses B-lymphocytes also generate anti-platelet antibodies. All these processes contributing to platelet activation result in increased platelet consumption and removal and often lead to thrombocytopenia, which is frequently observed during viral infection. However, virus-induced platelet activation does not only modulate platelet count but also shape immune responses. Platelets and their released products have been reported to directly and indirectly suppress infection and to support virus persistence in response to certain viruses, making platelets a double-edged sword during viral infections. This review aims to summarize the current knowledge on platelet interaction with different types of viruses, the viral impact on platelet activation, and platelet-mediated modulations of innate and adaptive immune responses. INTRODUCTION From an evolutionary perspective, the cellular mediators of hemostasis and immune defense have not always been separated. In invertebrates, a cell type called hemocyte protects the host from invading microbes and the same cell also prevents “blood” (i.e., hemolymph) loss upon injury by triggering coagulation (1, 2). In highly developed species, hemostasis and immune response have been divided and leukocytes resume the immune response functions, while platelets maintain hemostasis (2). For decades, these two systems were thought to act independently, but this concept has recently been challenged. Emerging evidence suggests that the boundaries between coagulation and immune defense are actually not as clear-cut as originally supposed. A new concept of involvement of immune cells in hemostasis, termed immunothrombosis, has been recently proposed, which assumes a function of innate immune cells in thrombosis (3). On the other hand, an important role of platelets in immune response becomes more and more apparent (4–7). In 1882, Bizzozero discovered platelets as the third morphological element in blood and elucidated the function of these cells in hemostasis and thrombosis (8). For a long time, platelets and their granule content were thought to mainly mediate the activation of the coagulation system and the recruitment of further platelets to stop blood loss upon injury. Unwanted platelet activation was noted to occur as a response to internal injuries, for example, denudation and erosion of the endothelial surface or rupture of an atherosclerotic plaque (9). Consequently, platelets were assumed to be responsible for the lethal steps of cardiovascular diseases, where unstable thrombi occlude small vessels, thereby compromising oxygen supply of target organs. Nevertheless, platelets are involved in far more processes and they respond to and interact with far more triggers than initially thought. Besides their central role in hemostasis, platelets assist and modulate inflammatory reactions and immune responses by direct interaction with leukocytes as well as endothelial cells and via release of soluble inflammatory mediators that enhance recruitment of leukocytes and trigger their activation (2, 4, 6, 10). Platelets also express surface receptors, such as lectins, integrins, and toll-like receptors (TLR), allowing them to directly interact with several pathogens. Moreover, they express Fc receptors by which they can recognize immunocomplexes. Thus, platelet activation does not only occur in response to injury and is not only limited to hemostatic processes but also modulates host response and virus survival (3–5, 7, 10–12). Therefore, potential immune-modulatory side effects should be considered during anti-platelet therapy. To date, the role of platelets in response to invading pathogens is not fully understood. Platelet–microbe interactions seem to be beneficial for the host due to up-regulation of immune responses. However, platelet interaction with invading pathogens is also speculated to benefit virus or bacteria, as platelets provide shelter against leukocytes, antiviral agents, and antibiotics. Moreover, the stickiness of platelets might attenuate microbe–endothelial interactions and facilitate infection by similar mechanisms to those recently described for platelet interactions with circulating tumor cells (13). This review aims to summarize the current knowledge on platelet interaction with different types of viruses, the viral impact on platelet activation, and platelet-mediated modulations of innate and adaptive immune responses. MECHANISMS OF VIRUS-INDUCED THROMBOCYTOPENIA Platelets are, after erythrocytes, the second most abundant cell population in the blood. Normal platelet counts range from 150,000 to 450,000 platelets per microliter. Thrombocytopenia, which represents a drop in platelet count caused by either decreased platelet production or increased platelet destruction, is associated with an increased bleeding risk. Thrombocytopenia is frequent following viral infections and viruses use a variety of distinct strategies to decrease the levels of circulating platelets. The different mechanisms of how virus infection can interfere with platelet production and might trigger platelet destruction are summarized in the first chapter and Figure 1. As virus-mediated thrombocytopenia is often multifactorial and differs between virus infections, the mechanisms by which viruses trigger thrombocytopenia are separately discussed for the most prominent viruses and an overview on the receptors involved in direct platelet–virus interactions is depicted in Figure 2. [Figure: Mechanisms of virus-induced thrombocytopenia: thrombocytopenia occurs either via decreased platelet production or increased platelet destruction. Viruses can trigger a decrease in platelet production by (I) infection of megakaryocytes, which can lead to (A) apoptosis of megakaryocytes, (B) decreased maturation and ploidy of megakaryocytes, or (C) decreased expression of thrombopoietin receptor c-Mpl. Viruses can also infect hematopoietic stem cells (II), which results (A) in a decrease of progenitor cells and (B) the induction of growth deficient megakaryocyte colony forming units, due to disturbed cytokine production by the infected cells in the bone marrow. Viruses can further indirectly influence platelet production (III) via induction of IFNα/β, which suppresses proplatelet formation or (IV) by targeting and modulating liver functions, which are important for the production of megakaryocyte growth and development factor thrombopoietin. Another mechanism for how viruses cause thrombocytopenia is by favoring platelet destruction, which frequently occurs during viremia. Viruses can either (V) directly interact with platelets or (VI) platelets recognize immunocomplexes of IgGs and viral antigens. Antiviral antigens often show cross-reactivity with platelet surface integrins (VII), which provides another mechanism of virus-induced destruction of platelets. The virus-induced pro-inflammatory environment itself often leads to further platelet activation in viremic patients (VIII). Additionally, changes in the portal vein pressure (IX) and an enlarged spleen (X) can serve as trigger for platelet activation. Once activated, platelets are recognized by circulating leukocytes or by cells in spleen and liver and rapidly cleared from the circulation. IFN, interferon, TPO, thrombopoietin; FcγRII, Fc receptor γ R II.] [Figure: Platelet receptors for viruses: platelets and viruses can directly interact via a plethora of surface receptors. CMV

Read the complete text